1. Scrip
  2. >>Business
  3. >>Strategy

Enterome Extends Its Microbiome Platform

 
• By Alex Lash

The French firm has partners for its diagnostics, wants to spin out a "stool banking" company, and might follow other microbiome start-ups into drug discovery to explore the connections between our bugs and our immune system.

It took a decade for the sequencing of the human genome to yield insights that filtered into therapeutic applications. So when similar work began a few years ago to decode the human microbiome, the trillions of microbes that live in and on the human body, wisdom held that it could take far longer to translate into help for patients. The slow flow of venture money into the area has reinforced that notion. (See[A#2012900157].)

"So far the momentum isn't remarkable," says Isabelle de Cremoux, CEO of diversified venture firm Seventure Partners. "Look at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.